First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study

Valladares Ayerbes, Manuel

Statistics

Statistics

View Usage Statistics

Identifiers

Identifiers

URI: http://hdl.handle.net/20.500.11940/7531

PMID: 22234633

DOI: 10.1634/theoncologist.2011-0249

ISSN: 1083-7159

Full record

Services

Services

RIS

Mendeley

Linksolver

Date issued

2012

Journal title

ONCOLOGIST

Type of content

Artigo